HomeIndustrySarepta Therapeutics Inc. (SRPT) Stock at a key inflection point

Sarepta Therapeutics Inc. (SRPT) Stock at a key inflection point

BTIG Research raised the price target for the Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock to “a Buy”. The rating was released on December 22, 2022, according to finviz. We previously noted in another research note published on December 16, 2022 by UBS that upgraded the stock from a Neutral to a Buy with a price target of $158 for SRPT stock. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Needham, who disclosed in a research note on January 05, 2022, to Buy and set the price objective to $150. In their research brief published December 09, 2021, Oppenheimer analysts upgraded the Sarepta Therapeutics Inc. stock from Perform to Outperform with a price target of $125.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Sarepta Therapeutics Inc. (NASDAQ:SRPT) raised 0.03% to close Tuesday’s market session at $128.37, higher as compared to yesterday’s close. The stock price fluctuated between $127.83 and $133.47 throughout the trading session with the volume trading being 1779724 shares, which represented a significant variation when compared to the three months average volume of 927.83K shares. The firm’s stock price fluctuated -1.25% within the last five trades and -2.31% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 54.29% in the last 6 months and 13.90% was added to its value over the previous 3 months. SRPT stock is trading at a margin of 2.05%, 6.21% and 29.66% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


As of the close of trading, SRPT deals in the Healthcare domain. The stock is trading -4.26 percent below its 52-week high and 109.48 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 84.82. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Sarepta Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -75.40 percent and the profit margin is -81.80 percent, and the company has reported a gross margin of 83.90 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $11.06 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 12.62 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 26.09, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.20 percent of Sarepta Therapeutics Inc. shares are owned by insiders, and 89.10 percent are held by financial institutions. Mayo Stephen, the Director at Sarepta Therapeutics Inc. (SRPT) has sold 858 shares of firm on Nov 17 at a price of $109.92 against the total amount of $94311.0. In another inside trade, Chambers Michael Andrew, Director of Sarepta Therapeutics Inc. (NASDAQ:SRPT) bought 57,100 shares of the firm on Sep 14 for a total worth of $5.96 million at a price of $104.43. An inside trade which took place on Aug 19, Director of Sarepta Therapeutics Inc. Chambers Michael Andrew bought 46,170 shares of firm against total price of $5.0 million at the cost of $108.28 per share.



Please enter your comment!
Please enter your name here

Recent Post